Serious Safety Concerns Regarding the Use of Melanotan II (Barbie Drug)
25 Jun 2025
Reference: CIR-2025-00000111
To all Health facilities and healthcare practitioners in Dubai's private health sector
Referring to the above subject, DHA notifies all health facilities regarding the circulars issued by the MOHAP for perusal and adherence to what is stated.
Circular No. 06 for the year 2025 Serious Safety Concerns Regarding the Use of Melanotan II (Barbie Drug)
Thanks in advance for your good co-operation
Drug Control Section
Health Regulation Sector
DHA
Do you find this Content helpful?